Access Risks Loom For All Drugmakers With Fourth Circuit Mifepristone Decision

 
• By Sarah Karlin-Smith
  
Yingyang with state and federal written on the two sides.
The balance of FDA and state authority in drug regulation may be upset by a recent US appeals court ruling. (Shutterstock)

More from Litigation

More from US FDA